Trovagene (TROV) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments
August 4, 2016 4:15 PM EDTSAN DIEGO, Aug. 4, 2016 /PRNewswire/ --Â Trovagene, Inc. (NASDAQ:Â TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today reported its financial results and accomplishments for the second quarter ended June 30, 2016.
"I'm excited to be part of the Trovagene team," said Bill Welch, Chief Executive Officer of Trovagene. "We announced a number of significant clinical study results, publications, and new collaborations with leading comprehensive cancer centers in the second quarter. Our focus remains on commercializing our highly sensitive and quantitative liquid biopsy... More
